Zolpidem

Generic Name
Zolpidem
Brand Names
Ambien, Edluar, Intermezzo, Tovalt
Drug Type
Small Molecule
Chemical Formula
C19H21N3O
CAS Number
82626-48-0
Unique Ingredient Identifier
7K383OQI23
Background

Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 . Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during s...

Indication

This drug is indicated for the short-term treatment of insomnia in adults characterized by difficulties with sleep initiation .

Associated Conditions
Insomnia
Associated Therapies
-
Clinical Trials
Related News

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

First Posted Date
2020-02-18
Last Posted Date
2023-12-18
Lead Sponsor
Walter Reed Army Institute of Research (WRAIR)
Target Recruit Count
90
Registration Number
NCT04273776
Locations
🇺🇸

Walter Reed Army Institute of Research, Silver Spring, Maryland, United States

Lavender vs Zolpidem Sleep Quality During Diagnostic PSG

Early Phase 1
Completed
Conditions
Sleep
Interventions
Other: Lavender Aromatherapy
Drug: Zolpidem
First Posted Date
2019-09-25
Last Posted Date
2021-03-17
Lead Sponsor
HealthPartners Institute
Target Recruit Count
58
Registration Number
NCT04102345
Locations
🇺🇸

Regions Hospital Sleep Center, Maplewood, Minnesota, United States

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

First Posted Date
2019-07-10
Last Posted Date
2023-10-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
60
Registration Number
NCT04014387
Locations
🇺🇸

University of California- San Francisco, San Francisco, California, United States

Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

Phase 2
Conditions
Insomnia Disorder
Interventions
Drug: Zolpidem
First Posted Date
2019-03-21
Last Posted Date
2020-07-27
Lead Sponsor
Biolab Sanus Farmaceutica
Target Recruit Count
366
Registration Number
NCT03885141

The Efficacy of Lower Dose Zolpidem for Achieving Satisfactory Sleep in Women With Disordered Sleep

Conditions
Sleep Disorder
Interventions
Drug: Zolpidem
First Posted Date
2018-12-24
Last Posted Date
2019-04-08
Lead Sponsor
Rhode Island Hospital
Target Recruit Count
50
Registration Number
NCT03786120
Locations
🇺🇸

rhode island Hospital, Sacramento, California, United States

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

First Posted Date
2018-09-05
Last Posted Date
2019-09-19
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
63
Registration Number
NCT03657355
Locations
🇨🇦

Altasciences Company Inc., Montreal, Canada

🇺🇸

Altasciences Clinical Kansas, Inc. (former Vince and Associates Clinical Research, Inc.), Overland Park, Kansas, United States

Enhancing Memory Consolidation in Older Adults

Phase 4
Conditions
Aging
Interventions
Drug: Zolpidem
First Posted Date
2018-09-04
Last Posted Date
2021-05-19
Lead Sponsor
University of California, Irvine
Target Recruit Count
30
Registration Number
NCT03657212
Locations
🇺🇸

Sleep and Cognition Lab, Irvine, California, United States

Use of Low-dose Zolpidem in Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson Disease
Interventions
Other: Placebo
Drug: Zolpidem
First Posted Date
2018-08-08
Last Posted Date
2020-03-27
Lead Sponsor
Aston University
Target Recruit Count
28
Registration Number
NCT03621046
Locations
🇬🇧

University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom

Optimize Astronaut Sleep Medication Efficacy and Individual Effects

Phase 4
Completed
Conditions
Cognition
Pharmacologic Actions
Sleep
Interventions
Drug: Zolpidem
First Posted Date
2018-05-16
Last Posted Date
2018-05-16
Lead Sponsor
National Aeronautics and Space Administration (NASA)
Target Recruit Count
34
Registration Number
NCT03526575

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Phase 1
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Zolpidem
First Posted Date
2018-02-19
Last Posted Date
2024-06-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
11
Registration Number
NCT03436745
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy